TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03173859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: apalutamide 240mg qD orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: apalutamide 240mg qD orally
Study: NCT03998111

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
Study: NCT00090194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10%
Study: NCT04459052

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: N acetyl cysteine
Description: Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18] Fluorodopa Positron Emission Tomography
Description: FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18] Fluorodopa Positron Emission Tomography
Description: FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
Study: NCT01057407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: oral
Study: NCT00254501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Counseling
Description: Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
Study: NCT01640509

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: treated by synchrotron radiation
Description: treated by synchrotron radiation
Study: NCT00817232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent (Elexoma Medic)
Description: monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent (Elexoma Medic)
Description: monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
Study: NCT00802204

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET scan
Description: Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological scales to assess attitudes and behaviors related to eating and quality of life
Description: A series of short psychological scales will be administered during the study. Completed at baseline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological scales to assess attitudes and behaviors related to eating and quality of life
Description: A series of short psychological scales will be administered during the study. Completed at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Obese participants only complete a short-term (\~10days) very low calorie diet
Study: NCT05103878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 100mg
Description: Single oral dose of 100mg BT051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 300mg
Description: Single oral dose of 300mg BT051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 700mg
Description: Single oral dose of 700mg BT051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 1500mg
Description: Single oral dose of 1500mg BT051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 3500mg
Description: Single oral dose of 3500mg BT051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo Matching BT051
Study: NCT02701387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Megagen AnyRidge dental implant
Description: AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Megagen EZ Plus dental implant
Description: EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
Study: NCT02495155

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROSPECT
Description: PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROSPECT
Description: PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROSPECT
Description: PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
Study: NCT02130739

Intervention type: PROCEDURE
Intervention: thoracic epidural anesthesia
Description: thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy

Intervention type: PROCEDURE
Intervention: mastectomy
Description: mastectomy with/without breast reconstruction

Intervention type: DRUG
Intervention: Ropivacaine
Description: Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine

Intervention type: DRUG
Intervention: Propofol
Description: Thoracic epidural anesthesia performed followed by sedation consisting of propofol

Intervention type: DRUG
Intervention: Fentanyl
Description: thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
Study: NCT03071614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT04097613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
Study: NCT03988530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Gel
Description: Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
Study: NCT03871322

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and K2 supplementation
Description: if supplementation of vitamin D and K2 changes the time to fracture healing

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: if supplementation of vitamin D alone changes the time to fracture healing

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group
Study: NCT01666509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rossoseq™

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02963545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care patients in neurology department
Description: patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood and urines sampling
Description: Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood and urines sampling
Description: Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
Study: NCT04170803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling
Study: NCT03926975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral Lens
Description: The contact lens will be worn on one eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No lens
Description: No lens worn on the contralateral control eye
Study: NCT02317211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch
Study: NCT03836495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lysine and phosphorus
Description: addition of lysine and essential amino acid and/or phosphorus an essential mineral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lysine and phosphorus
Description: addition of lysine and essential amino acid and/or phosphorus an essential mineral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lysine and phosphorus
Description: addition of lysine and essential amino acid and/or phosphorus an essential mineral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lysine and phosphorus
Description: addition of lysine and essential amino acid and/or phosphorus an essential mineral
Study: NCT01362361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + BIBF 1120
Description: mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFOX6+placebo
Description: mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
Study: NCT02829242

Intervention type: DEVICE
Intervention: NIRS Monitoring (SenSmart Monitor)

Intervention type: DEVICE
Intervention: NIRS Monitoring (SenSmart Monitor)
Study: NCT01003210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyland's earache drops
Description: 3-4 drops in affected ear 3 times a day as needed for up to 5 days
Study: NCT04666779

Intervention type: OTHER
Intervention: Chiropractic care
Description: Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
Study: NCT03269370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anchors Away
Description: Modular Cognitive Behavioral Therapy delivered through a mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Enhanced Anchors Away
Description: Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help E-Book
Description: Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)
Study: NCT00573209

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
Study: NCT00396201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT00904800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: tablet, oral, once daily, 1+5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: tablet, oral, once daily, 1+5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: tablet, oral, once daily, 1+5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02971631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Description: Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 1% human albumin in normal saline
Study: NCT01128127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group education, audit-feedback and computer support
Description: Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-feedback and computer support
Description: Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID.
Study: NCT01378234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Discharge Planning Program transitional care
Description: Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~1. Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~2. Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~3. Supporting caregivers to reduce stress and burden
Study: NCT01143727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: Apply one 24-hr period sufficient to cover the wound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm Hydrogel
Description: Apply once 24-hr period sufficient to cover the wound.
Study: NCT04207450

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel application followed by placebo solution application (distilled water)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gel + 5% Glutaraldehyde Aqueous Solution
Description: Placebo gel followed by 5% aqueous glutaraldehyde solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%
Description: 37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
Study: NCT04086004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Experimental Motor Imagery
Description: The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
Study: NCT02681679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac ophthalmic solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser cataract surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: femtosecond laser cataract surgery
Study: NCT01792804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Description: study drug 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: study drug 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: study drug 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Description: study drug 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Description: study drug 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: study drug 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: study drug 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: study drug 8